All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Deals, Development and Manufacturing
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
Global Perspectives
Intellectual Property & Patents
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
Mergers and Acquisitions
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Deals, Development and Manufacturing
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
Global Perspectives
Intellectual Property & Patents
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
Mergers and Acquisitions
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Trends: Holograms and Anticounterfeiting

April 2, 2008
By Ian Lancaster
News
Article
Pharmaceutical TechnologyPharmaceutical Technology-04-02-2008
Volume 32
Issue 4

Sophisticated replication techniques have made counterfeiting and fraud a serious threat to the pharmaceutical industry.

The World Health Organization estimates that annual earnings from the global sales of counterfeit and substandard medicines are more than $32 billion. Both drugs and packaging are counterfeited and people's lives have been put at risk. Diversion of legitimate products outside authorized distribution channels is another issue. To combat these problems, many of the world's leading pharmaceutical companies have directed efforts toward authenticating their packaging as part of the process of protecting their products. Diffractive optically variable devices—referred to generically as holograms—have become a widely used overt authentication feature on pharmaceutical products worldwide.

The above combination of a metallized, reflective holographic stripe and a clear holographic laminate on a vitamin package received an Excellence in Holography Award from the International Hologram Manufacturers Association in 2007. (PHOTO: PURA GROUP-TSS HOLOGRAPHICS/IHMA)

Since Glaxo (North Carolina) first used a tamper-evident hologram to seal packs of Zantac in 1989, holograms have been taken up in a big way by industry. Many major drug companies use holograms on at least some of their medicines in the form of labels, seals, hot-stamped patches, and blister-foils. The ability of the hologram to provide effective protection lies in the continuous innovation, invention, and evolution in holographic techniques that have succeeded in creating increasingly complex devices that are easily recognized yet difficult to copy accurately.

The evolving role of the hologram has also been accompanied by increased use of the security device in combination with other authentication technologies. In such solutions, holograms can provide overt first-line authentication while covert features such as scrambled images, microtext, UV-sensitive or other specialist inks provide second line authentication for trained examiners and appropriate decoding equipment.

Another recent trend is the serialization of holograms as part of systems that combine authentication with traceability. These "track-and-trace" systems link on-pack security devices with database management and field-tracking services. Manufacturers are able to tell where a pharmaceuticals consignment has been, where it's located, and where it's headed. This is particularly important in identifying the source and provenance of products.

While US Congress is currently considering making the use of security-marking on some pharmaceutical products mandatory using "overt optically variable counterfeit-resistant technologies" to protect consumers from fakes, the hologram is already specified as the authentication feature on the world's only statutory pharmaceutical marking scheme: the Meditag program in Malaysia. This program requires all registered medicines, over-the-counter pharmaceuticals, and traditional medicines to carry a uniquely numbered label built around a hologram. More recently, Nigeria's National Agency for Food & Drug Administration and Control has announced plans to introduce uniquely numbered holographic labels on all licensed medicines distributed in the country.

Perhaps unsurprisingly, the success and near ubiquitous use of holograms in anticounterfeiting applications has inevitably led to attempts to copy or replicate them. The intrinsic features of holograms, however, are very difficult to copy with 100% accuracy which makes them a preferred detection feature for packaging.

It is important to note, however, that it is the primary responsibility of manufacturers and regulators to ensure that fake pharmaceuticals not be able to enter the legitimate supply chain. A case in point occurred in Southeast Asia where it has been reported that more than half the sales of the antimalaria treatment Artesunate were for counterfeit versions despite the drug's blister-pack that contained a hologram. The point is, although regulators can identify fake holograms, the public cannot necessarily do so. Going forward, holograms will continue to evolve and for the time being, remain an integral part of anticounterfeiting strategies.

Ian Lancaster is general secretary at the International Hologram Manufacturers Association.

Articles in this issue

Suppositories: The Incomplete Story
i1-505377-1408663385436.jpg
A Transformation in the Making
i1-505365-1408663427499.jpg
Vapors, Venison, and Videos
Inside IPEC-EUROPE: Pharmaceutical Excipients—The View from the EU
i4-505378-1408663381861.gif
Measuring Excipient-Market Growth
Report From: China, May 2008
i2-505372-1408663403514.gif
Weak Link in the Pharmaceutical Supply Chain
Spectrophotometric Determination of Lead
i1-505364-1408663430939.jpg
Message in a Bottle
Tracking the Potential of Excipients
i1-505362-1408663435917.jpg
Coming Down the Pike: Bispecific mABs
Trends: Holograms and Anticounterfeiting
Equipment Hold-Time for Cleaning Validation
Science, Empiricism, and Off-label Use
i4-505465-1408663308187.jpg
Innovations at INTERPHEX
Recent Videos
Related Content

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Piramal Pharma to Invest $90 Million at Kentucky & Michigan Sites

Patrick Lavery
May 12th 2025
Article

The company said the investment is in response not only to customer demand and a belief in the value of US-based innovation, but also because of the trend toward US onshoring brought about by new tariff policies.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Mississauga, On, Canada - October 24, 2020: Astrazeneca Canada company sign is seen in Mississauga, Ontario, Canada. AstraZeneca plc is a British pharmaceutical and biopharmaceutical company. | Image Credit: © JHVEPhoto - stock.adobe.com

EU Approves AstraZeneca Mantle Cell Lymphoma Treatment

Patrick Lavery
May 9th 2025
Article

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with the current standard of care, according to a phase III trial.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Image Credit: © Alessandro Grandini - stock.adobe.com

Understanding the Variability in Bioburden Test Results in Biomanufacturing

Naveenganesh Muralidharan
May 7th 2025
Article

This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.


n-nitrosodimethylamine molecular structure, 3d model molecule, n-nitrosamines, structural chemical formula view from a microscope | Image Credit: © Сергей Шиманович - stock.adobe.com

Strategies for Mitigating Nitrosamine Risk

Susan Haigney
May 7th 2025
Article

Amit Chivate, senior market manager, Greater Asia and China, Roquette, provides his perspective on FDA’s recommendations regarding nitrosamines.

Related Content

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Piramal Pharma to Invest $90 Million at Kentucky & Michigan Sites

Patrick Lavery
May 12th 2025
Article

The company said the investment is in response not only to customer demand and a belief in the value of US-based innovation, but also because of the trend toward US onshoring brought about by new tariff policies.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Mississauga, On, Canada - October 24, 2020: Astrazeneca Canada company sign is seen in Mississauga, Ontario, Canada. AstraZeneca plc is a British pharmaceutical and biopharmaceutical company. | Image Credit: © JHVEPhoto - stock.adobe.com

EU Approves AstraZeneca Mantle Cell Lymphoma Treatment

Patrick Lavery
May 9th 2025
Article

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with the current standard of care, according to a phase III trial.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Image Credit: © Alessandro Grandini - stock.adobe.com

Understanding the Variability in Bioburden Test Results in Biomanufacturing

Naveenganesh Muralidharan
May 7th 2025
Article

This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.


n-nitrosodimethylamine molecular structure, 3d model molecule, n-nitrosamines, structural chemical formula view from a microscope | Image Credit: © Сергей Шиманович - stock.adobe.com

Strategies for Mitigating Nitrosamine Risk

Susan Haigney
May 7th 2025
Article

Amit Chivate, senior market manager, Greater Asia and China, Roquette, provides his perspective on FDA’s recommendations regarding nitrosamines.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.